Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 9/20 | 0.58 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CPS1 | P31327 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078079 | 0.90 | CCR1 (0.60) | CCR1PTGDR2ENPP2 | |
| SCHEMBL6077664 | 0.90 | CCR1 (0.70) | CCR1PTGDR2ENPP2 | |
| SCHEMBL6077196 | 0.88 | CCR1 (0.55) | CCR1PTGDR2CPS1ENPP2MEN1 | |
| SCHEMBL6076284 | 0.88 | CCR1 (0.72) | CCR1PTGDR2KDM4ELMNACYP1A2 | |
| SCHEMBL5066322 | 0.83 | CCR1 (0.73) | CCR1PTGDR2CPS1MEN1KMT2A | |
| SCHEMBL5066317 | 0.83 | CCR1 (0.73) | CCR1PTGDR2CPS1MEN1KMT2A | |
| SCHEMBL5066336 | 0.83 | CCR1 (0.73) | CCR1PTGDR2CPS1MEN1KMT2A | |
| SCHEMBL6076185 | 0.83 | CCR1 (0.55) | CCR1PTGDR2ENPP2 | |
| SCHEMBL4588383 | 0.81 | CCR1 (0.65) | CCR1CPS1MEN1KMT2A | |
| SCHEMBL4588377 | 0.81 | CCR1 (0.65) | CCR1CPS1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098212-B2 | Piperazine derivatives | BLUMBERG LAURA C | 2006-08-29 | — | — | US | disclosed |
| US-20040034034-A1 | Novel piperazine derivatives | BLUMBERG LAURA C (US) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034034-A1 | Novel piperazine derivatives | CCR1, CCRL2, CCR5 | CCR1 1/4885PTGDR2 190/4885KDM4E 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.